← Back to Westminster Hall Debates

Lobular Breast Cancer — [Valerie Vaz in the Chair]

10 December 2024

Lead MP

Helen Hayes
Dulwich and West Norwood
Lab

Responding Minister

Karin Smyth

Tags

NHSTaxation
Word Count: 10704
Other Contributors: 12

At a Glance

Helen Hayes raised concerns about lobular breast cancer — [valerie vaz in the chair] in Westminster Hall. A government minister responded.

Key Requests to Government:

The Minister is asked to investigate why there are few targeted programmes for diagnosing, researching and treating lobular breast cancer; ensure it remains a priority in the Government's women's health strategy; address lack of information on mammograms for non-lump changes; educate primary care doctors on symptoms; establish specific follow-up pathways for lobular patients; support Manchester Breast Centre's £20 million Lobular Moon Shot funding proposal.

How the Debate Unfolded

MPs spoke in turn to share their views and ask questions. Here's what each person said:

Lead Contributor

Dulwich and West Norwood
Opened the debate
Heather Cripps was diagnosed with stage 4 invasive lobular breast cancer during the COVID-19 pandemic, initially treated as a musculoskeletal issue before her back pain worsened. Lobular breast cancer accounts for 15% of all breast cancers in the UK, with 22 women diagnosed daily. It does not cause lumps and is often invisible on mammograms, leading to late diagnosis which impacts survival rates negatively. Dr Susan Michaelis's experience highlights that lobular breast cancer has no specific treatments. The Manchester Breast Centre proposes £20 million over five years for Lobular Moon Shot funding to understand the pathology of lobular cancer.

Government Response

Karin Smyth
Government Response
It is a real pleasure to serve under your chairship, Ms Vaz. I add my thanks to all hon. Members for their contributions and to my hon. Friend the Member for Dulwich and West Norwood (Helen Hayes). First let me say how sorry I am to hear about her friend. Those are very precious friendships and I think my hon. Friend articulated that well today. My deepest sympathies to Heather's loved ones who are with us today and to her wider family group. It is a really difficult time and this is a very recent bereavement to be talking about. My hon. Friend has used her voice as a parliamentarian to good effect, as she always does, and I congratulate her on doing that. I hope I can go some way to answering the questions she raised at the end of her speech. If I do not and she is not satisfied, I will make sure officials get back to her on the specifics. We know that too many cancer patients are being failed. They are waiting too long for life-saving treatments and receiving a diagnosis too late. As my right hon. and learned Friend the Prime Minister reiterated last week, we have inherited a broken NHS but it is not beyond repair. We know it needs to be fixed and there is not a single solution. To ensure that more people survive cancer, including lobular breast cancer, we have to take a multi-pronged approach—catching it earlier so more treatments are available, raising awareness of its specific symptoms, and investing in equipment and research, as many hon. Members have raised today. According to Cancer Research UK, lobular breast cancer is the second most common type of breast cancer, impacting around 15 out of every 100 breast cancers. Treatments for lobular breast cancer are broadly similar to those for other breast cancers but can be more challenging when the cancer has spread or developed in different ways. NHS England funded an audit into primary and metastatic breast cancer that began in October 2022, with results published in September this year. The take-up of breast cancer screening is currently below 70%, which is worryingly low, but we are determined to improve it. Every effort made by hon. Members and people listening to the debate can help save lives. My Department has invested £1.3 million in a Bristol-based FAST MRI project focusing on an abbreviated MRI that can help detect aggressive forms of breast cancer missed by screening through mammography, including lobular breast cancer. Additionally, we spend £125 million each year on cancer research combined with the Medical Research Council and UK Research and Innovation. Through the National Institute for Health and Care Research (NIHR), my Department encourages applications for new research in this area. The Lobular Moon Shot Project has already contracted £29 million to the Institute of Cancer Research and its partner at the Royal Marsden, focusing on lobular breast cancer. To improve outcomes for all tumour types, including lobular breast cancer, we are now in discussions about what form a national cancer plan should take. We have launched the biggest national conversation about the future of the NHS since its birth to shape the 10-year plan and encourage suggestions from hon. Members on how to prevent cancer where possible. Improving cancer survival requires a multi-pronged approach, ensuring that patients have timely access to effective treatments built on world-class research. We have committed to surgical hubs, scanners for an additional 30,000 procedures each year and £70 million for radiotherapy machines.
Assessment & feedback
Summary accuracy

About Westminster Hall Debates

Westminster Hall debates are a chance for MPs to raise important issues affecting their constituents and get a response from a government minister. Unlike Prime Minister's Questions, these debates are more in-depth and collaborative. The MP who secured the debate speaks first, other MPs can contribute, and a minister responds with the government's position.